Functional consequence and therapeutic targeting of cryptic ALK fusions in monosomy 7 acute myeloid leukemia

Functional consequence and therapeutic targeting of cryptic ALK fusions in monosomy 7 acute myeloid leukemia

Acute myeloid leukemia (AML) patients have a wide array of cytogenetic and molecular aberrations, which can influence response to therapy. Monosomy 7 is a rare subset within pediatric AML (prevalence of

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pediatric blood & cancer 2023-04, Vol.70 (4), p.e30180-n/a
Hauptverfasser: Manselle, Makia K., Ries, Rhonda E., Hylkema, Tiffany, Leonti, Amanda, Kirkey, Danielle C., Furlan, Scott N., Meshinchi, Soheil
Format: Artikel
Sprache:eng
Schlagworte:
Acute myeloid leukemia
AML
cancer genetics
chemotherapy
Child
Chromosome Deletion
Crizotinib - therapeutic use
Cytogenetics
Hematology
hematology/oncology
Humans
Leukemia, Myeloid, Acute - drug therapy
Monosomy
Oncology
Pediatrics
Protein Kinase Inhibitors - therapeutic use
Protein-tyrosine kinase
Receptor Protein-Tyrosine Kinases - genetics
Receptor Protein-Tyrosine Kinases - therapeutic use
Therapeutic targets
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Acute myeloid leukemia (AML) patients have a wide array of cytogenetic and molecular aberrations, which can influence response to therapy. Monosomy 7 is a rare subset within pediatric AML (prevalence of
ISSN:1545-5009
1545-5017
DOI:10.1002/pbc.30180